- In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize a COVID-19 Varicocele and collaborate on the development of innovative combination Varicoceles targeting both COVID-19 and influenza. This strategic alliance enables both companies to utilize their respective expertise and resources to deliver advanced Varicocele solutions to the market
- In March 2023, CSL Limited opened a new Varicocele research and development facility in Waltham, Massachusetts, aimed at creating advanced Varicoceles utilizing disruptive technologies, including next-generation mRN
Frequently Asked Questions
The market is segmented based on Segmentation By Grade (Grade 0, Grade 1, Grade2, Grade3, and Others), Treatment (Medication, Varicocele Embolization, Varicocele Repair, and Others), Diagnosis (Physical Exam, Scrotal Ultrasound, Thermography, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Varicocele Market size was valued at USD 599.11 USD Million in 2024.
The Global Varicocele Market is projected to grow at a CAGR of 7.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
